SCHEMBL379469

SCHEMBL379469

Cc1ccc(-c2csc3c(-c4ccc(O)cc4)cnc(NCc4ccccc4)c23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.49
KDR P35968 6/20 0.47
TP53 P04637 1/20 0.44
CCNC P24863 1/20 0.44
CDK8 P49336 1/20 0.44
AURKB Q96GD4 3/20 0.43
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
FGFR1 P11362 3/20 0.41
PLK4 O00444 2/20 0.41
AURKA O14965 2/20 0.41
ROCK2 O75116 2/20 0.41
MAP4K4 O95819 2/20 0.41
ABL1 P00519 2/20 0.41
NTRK1 P04629 2/20 0.41
INSR P06213 2/20 0.41
FYN P06241 2/20 0.41
CSF1R P07333 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379874 0.94 CCNC (0.47) ESR1KDRTP53CCNCCDK8
SCHEMBL379662 0.93 CCNC (0.49) ESR1KDRTP53CCNCCDK8
SCHEMBL380180 0.91 ESR1 (0.50) ESR1KDRTP53CCNCCDK8
SCHEMBL379876 0.90 BTK (0.47) ESR1KDRTP53CCNCCDK8
SCHEMBL379872 0.90 CCNC (0.42) ESR1KDRTP53CCNCCDK8
SCHEMBL379543 0.89 THRB (0.44) ESR1KDRTP53CCNCCDK8
SCHEMBL379554 0.89 BRAF (0.52) ESR1KDRCCNCCDK8AURKB
SCHEMBL379842 0.88 CYP1A2 (0.54) ESR1KDRTP53CCNCCDK8
SCHEMBL379860 0.85 CCNC (0.42) ESR1KDRTP53CCNCCDK8
SCHEMBL379947 0.85 KDR (0.45) ESR1KDRTP53CCNCCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US claimed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 ESR1 4761/4885KDR 2522/4885TP53 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.